New COVID Vaccine Highly Effective Against Severe Disease, Companies Say

They will also ask the FDA and other regulators to consider it as a booster candidate.

Novavax, a similar vaccine, submitted data for authorization to the FDA last month.

The Sanofi-GSK vaccine was one which received funding fromOperation Warp Speed.

However,progress was delayedin 2020 when the vaccine failed to produce a strong immune response in older adults.

The companies then began working on a stronger version.

Read more:Here’s How Long Your COVID Vaccine Booster Provides Protection